drugset / Trial / NCT05012371
Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer
Phase 2
Active not recruiting
90 enrolled
M.D. Anderson Cancer Center
National Cancer Institute (NCI) · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This phase II trial compares the effects of lenvatinib given in combination with everolimus to the effects of cabozantinib given alone in treating patients with renal cell cancer (RCC) that has spread to other parts of the body (metastatic) and that got worse on a previous PD-1/PD-L1 checkpoint inhibitor. Lenvatinib, everolimus, and cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Timeline
- Start
- 2022-02-16
- Primary completion
- 2027-10-25
- Completion
- 2027-10-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Cabozantinib | Small molecule | — | Oral |
| Subject | Everolimus | Small molecule | — | Oral |
| Subject | Lenvatinib | Small molecule | — | Oral |